AOD-9604 vs SHLP2

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.

Full details →

SHLP2

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Full details →

Side-by-Side Comparison

Aspect	AOD-9604	SHLP2
Dose Range	300 mcg–500 mcg	1 mg–5 mg
Frequency	1x daily	1x daily
Cycle Length	12–24 weeks	4–8 weeks
Route	subcutaneous	subcutaneous
Mechanism	Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors.	Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Typical Dosage	Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg.	Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Administration	Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects.	Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Side Effects	Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH.	Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Best For	Fat Loss	Fat Loss Anti-Aging & Longevity